Travere Therapeutics, Inc. (TVTX)
Every FINRA and SEC series the site collects for Travere Therapeutics, Inc.: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
11.9M
Short interest
settlement 2026-08-14
5.7
Days to cover
+2.3% vs prior
64.3%
Short share of volume
2026-09-11
78,400
Fails to deliver
settlement 2026-08-14
-$2.0M
Insider flow, 90 days
0 buys, 10 sells
As of 2026-09-11.
Short interest
FINRA, twice a month; the last 12 months shown, all 48 settlements in the JSONAs of 14 August 2026, short interest in TVTX is 11,943,638 shares, down 71,754 shares over the last month. Over the last 48 readings it ranged from 6,962,090 shares (30 September 2024) to 15,365,503 shares (15 January 2026). At the reported average volume of 2.1M shares a day that is 5.7 days to cover, elevated.
Embed this chartfree, with the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/tvtx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-08-14 | 11,943,638 | +2.3% | 2,095,016 | 5.70 |
| 2026-07-31 | 11,676,586 | -2.8% | 1,240,232 | 9.41 |
| 2026-07-15 | 12,015,392 | -5.3% | 1,312,513 | 9.15 |
| 2026-06-30 | 12,687,615 | -5.6% | 2,692,053 | 4.71 |
| 2026-06-15 | 13,437,418 | -4.8% | 2,103,228 | 6.39 |
| 2026-05-29 | 14,122,154 | +0.8% | 1,729,763 | 8.16 |
| 2026-05-15 | 14,008,379 | -1.5% | 3,128,402 | 4.48 |
| 2026-04-30 | 14,216,705 | +11.7% | 1,974,002 | 7.20 |
| 2026-04-15 | 12,725,544 | -5.4% | 3,410,312 | 3.73 |
| 2026-03-31 | 13,446,405 | +0.5% | 1,221,504 | 11.01 |
| 2026-03-13 | 13,383,909 | -5.6% | 1,258,175 | 10.64 |
| 2026-02-27 | 14,180,739 | -6.8% | 1,463,647 | 9.69 |
| 2026-02-13 | 15,217,326 | +5.0% | 1,413,273 | 10.77 |
| 2026-01-30 | 14,491,659 | -5.7% | 1,671,645 | 8.67 |
| 2026-01-15 | 15,365,503 | +7.3% | 4,452,964 | 3.45 |
| 2025-12-31 | 14,312,827 | +17.4% | 1,957,813 | 7.31 |
| 2025-12-15 | 12,196,281 | +11.2% | 1,513,672 | 8.06 |
| 2025-11-28 | 10,969,722 | +5.9% | 1,313,897 | 8.35 |
| 2025-11-14 | 10,355,808 | -4.8% | 2,152,492 | 4.81 |
| 2025-10-31 | 10,879,506 | -8.1% | 2,183,311 | 4.98 |
| 2025-10-15 | 11,840,340 | +5.3% | 1,631,893 | 7.26 |
| 2025-09-30 | 11,241,968 | -8.7% | 2,111,348 | 5.32 |
| 2025-09-15 | 12,319,282 | +2.0% | 3,781,660 | 3.26 |
| 2025-08-29 | 12,081,747 | -0.2% | 1,650,536 | 7.32 |
Daily short volume
FINRA Reg SHO, last 60 sessions. JSONAs of 11 September 2026, the short share of TVTX volume is 64.3%, up 0.3 points over the last five sessions. Over the last 52 readings it ranged from 28.2% (5 August 2026) to 78.6% (27 August 2026). The latest reading is 4.1 points above the 30-session average of 60.2%, on 402K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-09-11 | 259K | 402K | 64.3% | 24,296 |
| 2026-09-10 | 359K | 511K | 70.3% | 2 |
| 2026-09-09 | 232K | 393K | 58.9% | 0 |
| 2026-09-08 | 376K | 565K | 66.6% | 60 |
| 2026-09-04 | 259K | 330K | 78.5% | 0 |
| 2026-09-03 | 231K | 361K | 64.0% | 668 |
| 2026-09-02 | 214K | 350K | 61.0% | 0 |
| 2026-09-01 | 205K | 404K | 50.7% | 3,307 |
| 2026-08-31 | 210K | 309K | 67.8% | 3,900 |
| 2026-08-28 | 220K | 331K | 66.5% | 239 |
| 2026-08-27 | 239K | 304K | 78.6% | 0 |
| 2026-08-26 | 310K | 498K | 62.3% | 0 |
| 2026-08-25 | 259K | 403K | 64.4% | 0 |
| 2026-08-24 | 227K | 371K | 61.2% | 0 |
| 2026-08-21 | 356K | 500K | 71.2% | 33,030 |
| 2026-08-20 | 176K | 339K | 51.7% | 0 |
| 2026-08-19 | 212K | 621K | 34.1% | 5,642 |
| 2026-08-18 | 209K | 358K | 58.4% | 0 |
| 2026-08-17 | 280K | 429K | 65.1% | 0 |
| 2026-08-14 | 359K | 486K | 73.9% | 453 |
| 2026-08-13 | 313K | 560K | 55.9% | 0 |
| 2026-08-12 | 331K | 492K | 67.2% | 10,652 |
| 2026-08-11 | 246K | 421K | 58.4% | 9,354 |
| 2026-08-10 | 188K | 327K | 57.4% | 7,437 |
| 2026-08-07 | 253K | 455K | 55.7% | 13,197 |
| 2026-08-06 | 491K | 1.1M | 44.8% | 52,868 |
| 2026-08-05 | 906K | 3.2M | 28.2% | 18,343 |
| 2026-08-04 | 557K | 1.0M | 54.2% | 0 |
| 2026-08-03 | 438K | 763K | 57.4% | 100 |
| 2026-07-31 | 435K | 746K | 58.3% | 0 |
Fails to deliver
SEC, by settlement date. JSONAs of 14 August 2026, the fails-to-deliver balance in TVTX is 78,400 shares, up 72,194 shares over the last settlement date. Over the last 52 readings it ranged from 14 shares (24 March 2026) to 89,520 shares (30 June 2026).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-14 | 78,400 | $61.43 | $4.8M |
| 2026-08-12 | 6,206 | $60.21 | $374K |
| 2026-08-04 | 150 | $54.98 | $8K |
| 2026-07-30 | 604 | $55.56 | $34K |
| 2026-07-17 | 54 | $55.28 | $3K |
| 2026-07-16 | 1,222 | $56.74 | $69K |
| 2026-07-07 | 63,225 | $57.48 | $3.6M |
| 2026-07-02 | 1,923 | $56.34 | $108K |
| 2026-07-01 | 140 | $56.81 | $8K |
| 2026-06-30 | 89,520 | $58.30 | $5.2M |
| 2026-06-29 | 31,945 | $58.85 | $1.9M |
| 2026-06-26 | 23 | $59.03 | $1K |
| 2026-06-23 | 17 | $55.11 | $937 |
| 2026-06-22 | 200 | $55.15 | $11K |
| 2026-06-15 | 672 | $52.04 | $35K |
| 2026-06-09 | 14,263 | $47.08 | $672K |
| 2026-06-08 | 40,947 | $45.81 | $1.9M |
| 2026-06-05 | 933 | $46.18 | $43K |
| 2026-04-28 | 621 | $40.81 | $25K |
| 2026-04-27 | 1,305 | $40.50 | $53K |
| 2026-04-23 | 517 | $40.09 | $21K |
| 2026-04-22 | 4,184 | $38.78 | $162K |
| 2026-04-21 | 2,930 | $40.29 | $118K |
| 2026-04-20 | 7,615 | $40.77 | $310K |
| 2026-04-15 | 59,592 | $42.13 | $2.5M |
| 2026-04-14 | 2,439 | $30.70 | $75K |
| 2026-04-06 | 74,414 | $30.44 | $2.3M |
| 2026-04-02 | 513 | $31.42 | $16K |
| 2026-03-24 | 14 | $27.75 | $389 |
| 2026-03-23 | 57 | $26.84 | $2K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONInsiders at TVTX reported 10 open-market sells worth $2.0M in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: Meckler Jeffrey A on 2026-09-10.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-10 | Meckler Jeffrey A | n/a | Sell | 3K | $68.09 | $211K | 92K |
| 2026-09-10 | Meckler Jeffrey A | n/a | Sell | 14K | $67.46 | $944K | 95K |
| 2026-09-10 | Meckler Jeffrey A | n/a | Sell | 1K | $66.15 | $79K | 109K |
| 2026-09-10 | Meckler Jeffrey A | n/a | Sell | 2K | $65.39 | $111K | 110K |
| 2026-09-10 | Meckler Jeffrey A | n/a | Option exercise | 10K | $17.44 | $174K | 102K |
| 2026-09-02 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 642 | $66.37 | $43K | 118K |
| 2026-08-18 | LYONS GARY A | n/a | Sell | 900 | $63.86 | $57K | 62K |
| 2026-08-18 | LYONS GARY A | n/a | Sell | 4K | $63.27 | $259K | 62K |
| 2026-08-18 | LYONS GARY A | n/a | Option exercise | 5K | $17.44 | $87K | 67K |
| 2026-08-17 | LYONS GARY A | n/a | Sell | 500 | $64.16 | $32K | 62K |
| 2026-08-17 | LYONS GARY A | n/a | Sell | 3K | $63.50 | $165K | 62K |
| 2026-08-17 | LYONS GARY A | n/a | Sell | 2K | $62.53 | $119K | 65K |
| 2026-08-17 | LYONS GARY A | n/a | Option exercise | 5K | $17.44 | $87K | 67K |
| 2026-06-12 | Baynes Roy D. | n/a | Sell | 5K | $50.00 | $225K | 42K |
| 2026-06-12 | Baynes Roy D. | n/a | Option exercise | 5K | $21.38 | $96K | 46K |
| 2026-05-19 | Williams Brinkley Ruth | n/a | Grant | 4K | $0.00 | $0 | 30K |
| 2026-05-19 | Squarer Ron | n/a | Grant | 4K | $0.00 | $0 | 39K |
| 2026-05-19 | Poole Sandra | n/a | Grant | 4K | $0.00 | $0 | 34K |
| 2026-05-19 | Orwin John A | n/a | Grant | 4K | $0.00 | $0 | 39K |
| 2026-05-19 | Meckler Jeffrey A | n/a | Grant | 4K | $0.00 | $0 | 92K |
| 2026-05-19 | LYONS GARY A | n/a | Grant | 4K | $0.00 | $0 | 62K |
| 2026-05-19 | Coughlin Timothy | n/a | Grant | 4K | $0.00 | $0 | 56K |
| 2026-05-19 | Bruhn Suzanne Louise | n/a | Grant | 4K | $0.00 | $0 | 33K |
| 2026-05-19 | Baynes Roy D. | n/a | Grant | 4K | $0.00 | $0 | 42K |
| 2026-05-15 | Coughlin Timothy | n/a | Sell | 3K | $43.49 | $141K | 52K |
| 2026-05-06 | ROTE WILLIAM E. | Chief Research Officer | Sell | 3K | $43.95 | $121K | 115K |
| 2026-05-06 | REED ELIZABETH E | Chief Legal Officer and GC | Sell | 2K | $43.95 | $91K | 105K |
| 2026-05-06 | Inrig Jula | CHIEF MEDICAL OFFICER | Sell | 311 | $43.95 | $14K | 113K |
| 2026-05-06 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 23K | $43.95 | $989K | 433K |
| 2026-05-06 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 310 | $43.95 | $14K | 119K |
| 2026-05-05 | REED ELIZABETH E | Chief Legal Officer and GC | Sell | 2K | $46.65 | $101K | 107K |
| 2026-05-05 | Inrig Jula | CHIEF MEDICAL OFFICER | Sell | 2K | $46.65 | $101K | 114K |
| 2026-05-05 | Heerma Peter | CHIEF COMMERCIAL OFFICER | Sell | 2K | $46.65 | $101K | 141K |
| 2026-05-05 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 2K | $46.65 | $102K | 119K |
| 2026-05-05 | Baynes Roy D. | n/a | Sell | 5K | $46.65 | $210K | 38K |
| 2026-05-05 | Baynes Roy D. | n/a | Option exercise | 5K | $18.27 | $82K | 42K |
| 2026-05-04 | ROTE WILLIAM E. | Chief Research Officer | Option exercise | 4K | $0.00 | $0 | 118K |
| 2026-05-04 | REED ELIZABETH E | Chief Legal Officer and GC | Option exercise | 4K | $0.00 | $0 | 109K |
| 2026-05-04 | REED ELIZABETH E | Chief Legal Officer and GC | Sell | 20K | $45.00 | $900K | 105K |
| 2026-05-04 | REED ELIZABETH E | Chief Legal Officer and GC | Option exercise | 20K | $17.96 | $359K | 125K |
| 2026-05-04 | Meckler Jeffrey A | n/a | Sell | 8K | $45.00 | $360K | 88K |
| 2026-05-04 | Meckler Jeffrey A | n/a | Option exercise | 8K | $16.33 | $131K | 96K |
| 2026-05-04 | Inrig Jula | CHIEF MEDICAL OFFICER | Option exercise | 4K | $0.00 | $0 | 116K |
| 2026-05-04 | Inrig Jula | CHIEF MEDICAL OFFICER | Sell | 20K | $45.00 | $900K | 111K |
| 2026-05-04 | Inrig Jula | CHIEF MEDICAL OFFICER | Option exercise | 20K | $22.40 | $448K | 131K |
| 2026-05-04 | Heerma Peter | CHIEF COMMERCIAL OFFICER | Option exercise | 4K | $0.00 | $0 | 143K |
| 2026-05-04 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Option exercise | 23K | $0.00 | $0 | 455K |
| 2026-05-04 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Option exercise | 4K | $0.00 | $0 | 121K |
| 2026-05-01 | Baynes Roy D. | n/a | Sell | 10K | $44.22 | $431K | 38K |
| 2026-05-01 | Baynes Roy D. | n/a | Option exercise | 10K | $6.82 | $66K | 47K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.
Planned sales (Form 144)
Newest first. JSON3 Form 144 notices on file for TVTX worth $2.0M at the prices reported; 3 in the last 90 days worth $2.0M. Latest: JEFFREY MECKLER filed on 2026-09-10 to sell 20,000 shares ($1.3M) from 2026-09-10.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-10 | JEFFREY MECKLERDirector | 20K | $1.3M | 0.021% | 2026-09-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-18 | GARY LYONSDirector | 5K | $318K | 0.005% | 2026-08-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-17 | GARY A LYONSDirector | 5K | $311K | 0.005% | 2026-08-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
13F holders
Tracked managers holding TVTX at their latest 13F. JSON9 of the 30 tracked managers held TVTX at their latest 13F, $331.4M in total at quarter-end prices. Renaissance Technologies is the largest at $104.1M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 6 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Renaissance Technologies | 2026-06-30 | 1.8M | $104.1M | 0.14% | -134K |
| Two Sigma Investments | 2026-06-30 | 1.6M | $88.9M | 0.06% | -1.4M |
| D. E. Shaw & Co. | 2026-06-30 | 1.4M | $81.8M | 0.04% | +604K |
| Point72 Asset Management | 2026-06-30 | 479K | $27.2M | 0.03% | -725K |
| AQR Capital Management | 2026-06-30 | 270K | $15.3M | 0.01% | -35K |
| D. E. Shaw & Co. | 2026-06-30 | 6.5M | $7.6M | 0.00% | +5.1M |
| Millennium Management | 2026-06-30 | 85K | $4.8M | 0.00% | +65K |
| Fisher Asset Management | 2026-06-30 | 16K | $900K | 0.00% | -18K |
| Two Sigma Investments | 2026-06-30 | 500K | $588K | 0.00% | -1.1M |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 2026 (quarter ended 2026-06-30) Travere Therapeutics, Inc. reported revenue of $169.6M, up 48.2% from the same quarter a year earlier, and net loss of $34.8M (-0.37 diluted EPS). In FY 2025 it generated $37.8M of operating cash flow.
- Cash
- $117.7M
- Equity
- $24.5M
- Total assets
- $799.4M
- Shares outstanding
- 94,261,082
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $169.6M | -$34.8M | -20.5% | -0.37 |
| Q1 2026 | 2026-03-31 | $127.2M | -$37.1M | -29.2% | -0.40 |
| Q4 2025derived | 2025-12-31 | $129.7M | n/a | n/a | n/a |
| Q3 2025 | 2025-09-30 | $164.9M | $25.7M | 15.6% | 0.28 |
| Q2 2025 | 2025-06-30 | $114.4M | -$12.8M | -11.1% | -0.14 |
| Q1 2025 | 2025-03-31 | $81.7M | -$41.2M | -50.4% | -0.47 |
| Q4 2024derived | 2024-12-31 | $74.8M | n/a | n/a | n/a |
| Q3 2024 | 2024-09-30 | $62.9M | -$54.8M | -87.1% | -0.70 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $490.7M | n/a | $37.8M | n/a | n/a | n/a |
| FY 2024 | 2024-12-31 | $233.2M | n/a | -$237.5M | n/a | n/a | n/a |
| FY 2023 | 2023-12-31 | $145.2M | n/a | -$280.0M | $668K | n/a | n/a |
| FY 2022 | 2022-12-31 | $109.5M | n/a | -$186.3M | $191K | n/a | n/a |
| FY 2021 | 2021-12-31 | $131.8M | n/a | -$14.8M | $5.1M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-30 from the cover page.
What this page is
Travere Therapeutics, Inc. in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.
This page follows Travere Therapeutics, Inc. (TVTX), SEC CIK 1438533, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and method
- Short interest
- FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-14.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-11.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-08-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144EDGAR read every 30 minutes; a notice is filed on or before the sell order. Latest 2026-09-10.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC XBRL company factsRefreshed weekly from the SEC's structured data; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-09-10.JSON and CSV
- Company record
- EDGAR filing index for CIK 1438533Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 30 requests a minute without a key, 120 a minute with a key from a free account.
Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 13 Sep 05:40 UTC.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
- UTHRUNITED THERAPEUTICS Corp
- CPIXCUMBERLAND PHARMACEUTICALS INC
- LLYELI LILLY & Co
- ALNYALNYLAM PHARMACEUTICALS, INC.
- PTCTPTC THERAPEUTICS, INC.
- MDGLMADRIGAL PHARMACEUTICALS, INC.
- ONCBeOne Medicines Ltd.
- IONSIONIS PHARMACEUTICALS INC
- INSMINSMED Inc
- CORTCORCEPT THERAPEUTICS INC
- ROIVRoivant Sciences Ltd.
- BBIOBridgeBio Pharma, Inc.
- CYTKCYTOKINETICS INC
- VRTXVERTEX PHARMACEUTICALS INC / MA
- LGNDLIGAND PHARMACEUTICALS INC
- LQDALiquidia Corp
- SIONSionna Therapeutics, Inc.
- JAZZJazz Pharmaceuticals plc
- BLTEBELITE BIO, INC
- PAHCPHIBRO ANIMAL HEALTH CORP
- ARQTArcutis Biotherapeutics, Inc.
- NATRNATURES SUNSHINE PRODUCTS INC
- HOWLWerewolf Therapeutics, Inc.
- JNJJOHNSON & JOHNSON
Datasets
Frequently Asked Questions
How much of TVTX is sold short?
What is TVTX's daily short volume?
Does TVTX have fails to deliver?
Are TVTX insiders buying or selling?
Have TVTX insiders filed to sell?
What did TVTX report last quarter?
Which funds hold TVTX?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.